Tratamiento oncológico de los tumores neuroendocrinos pancreáticos
Oncological treatment of pancreatic neuroendocrine tumors
Palabras clave:
Neoplasias neuroendocrinas gastroenteropancreáticas, GEP-NENs, GEP-NET, Pan-NENs, SI-NET, tratamiento, análogos de la somatostatina, telotristat, everolimus, sunitinib
Resumen
El tratamiento médico de los tumores neuroendocrinos pancreáticos (Pan-NENs) es todo un desafío, y las decisiones de tratamiento deben ser realizadas en conjunto por el equipo multidisciplinario e individualizadas. Para enfermedad avanzada, el conocimiento de los síntomas funcionales o de los derivados de la proliferación celular son claves para diseñar el mismo. El objetivo de esta revisión es describir cada una de las opciones de terapéuticas con los niveles de evidencia y grado de recomendación de la Sociedad Europea de Medicina oncológica (ESMO).
Descargas
La descarga de datos todavía no está disponible.
Citas
Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoides) tumours. Aliment Pharmacol Ther 2010;31: 169-188.
Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose Octeotride-LAR: a systematic literature review. World J Gastroenterol 2015;21:1945-1955.
Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015;9:5075-5086.
Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a revew. Digestion 2000;62(Suppl 1):92-97.
Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome J Clin Oncol 2017;35:14y23.
Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELESCAT phase 3 trial. Endocr Relat Cancer 2018;25:309-322.
Cella D, Beaumont JL, Hudgens S, et al. Relationship between symptoms and health- related quality-of-life benefits in patients with carcinoid syndrome: Post hoc analyses from TELESTAR. Clin Ther 2018;40:2006-2020.
Bushnell Jr DL, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octeotride. J Clin Oncol 2010;28: 1652-1659.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018;36:2578-2584.
Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother 2016;17:2191-2205.
Zandee WT, Brabander T, Blazevic A, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104:1336e1344.
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo- controlled, double-blind, prospective, randomized study on the effect of octreoide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224-233.
Caplin ME, Pavel M, Cwikla JB, et al. Anti-tumor effects of Lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 2016;23:191-199.
Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long- term survival. Neuroendocrinology 2017;104:26-32.
Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparision trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017;35:1695- 1703.
Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2017;28:1309-1315.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from randomized, phase III RADIANT-3 study. J Clin Oncol 2016;34:3906-3913.
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo- controlled, phase 3 study. Lancet. 2016;387:968-977.
Singh S, Carnaghi C, Buzzoni R, et al. Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology 2018;106:211-220.
Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1411-1422.
Pavel ME, Hainsworth JD, Baudin E, eta l. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;378:2005-2012.
Pavel ME, Baudin E, Oberg KE, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumors and carcinoid syndrome: final overall survival from the ramdomized, placebo-controlled, phase 3 trial RADIANT-2 study. Ann Oncol 2017;28:1569-1575.
Ema. Available at https://www.ema.europa.eu/en/documents/product-information/a finitor-epar-product-information_en.pdf. Accessed November 29, 2019.
Panzuto F, Rinzivillo M, Spada F, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas 2017;46:302-305.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 501-513.
Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017;28:339-343.
Vinik A, Bottomley A, Korytowsky B, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from international phase III trial. Target Oncol 2016;11:815-824.
Ema. Available at https://ec.europa.eu/health/documents/community- register/2016/20161109136193/anx_136193_en.pdf. Accessed November 29, 2019.
Raymond E, Kulke MH, Qin S, et al. Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours. Neuroendocrinology 2018;107:237-245.
Pellat A, Dreyer C, Couffignal C, et al. Clinical and biomarker evaluations of sunitinib in patients with Grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107:24-31.
Xu J, Shen L, Zhou Z, et al. Efficacy and safety of surufatinib in patients with well- differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the ramdomize phase III study (SANET-ep). Ann Oncol 2019; 30:v851-v934.
Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cáncer Tratar Rev. 2016;44:26-41.
Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin- fluoracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
Clewemar Antonodimitrakis P, Sundin A, Wassberg C, et al. Streptozocin and 5- fluoracil for the treatment of pancreatic neuroendocrine tumors: Efficacy, prognostic factors and toxicity. Neuroendocrinology 2016;103:345-353.
Dilz LM, Denecke T, Steffen IG, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015;51:1253-1262.
Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Cancer de Endocr Relat. 2016;23:759-767.
Kunz PL, Catalano PJ, Nimeiri HS, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumours: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol 2015; 33:TPS4145.
Walter T, van Brakel B, Vercherat C, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 2015;112:523-531.
Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014;120:2814-2023.
Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high- grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinoma. Neuroendocrinology. 2016;103:186-194.
Knigge U, Capdevila J, Bartsch DK, et al. ENETS Consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology 2017;105:310- 319.
Ema. Available in https://www.ema.europa.eu/en/documents/overvi ew/lutathera- epar-summary-public_en.pdf. Accessed November 29, 2019.
Oberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol 2020;31:202-212.
Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose Octeotride-LAR: a systematic literature review. World J Gastroenterol 2015;21:1945-1955.
Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015;9:5075-5086.
Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a revew. Digestion 2000;62(Suppl 1):92-97.
Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome J Clin Oncol 2017;35:14y23.
Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELESCAT phase 3 trial. Endocr Relat Cancer 2018;25:309-322.
Cella D, Beaumont JL, Hudgens S, et al. Relationship between symptoms and health- related quality-of-life benefits in patients with carcinoid syndrome: Post hoc analyses from TELESTAR. Clin Ther 2018;40:2006-2020.
Bushnell Jr DL, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octeotride. J Clin Oncol 2010;28: 1652-1659.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018;36:2578-2584.
Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother 2016;17:2191-2205.
Zandee WT, Brabander T, Blazevic A, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104:1336e1344.
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo- controlled, double-blind, prospective, randomized study on the effect of octreoide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224-233.
Caplin ME, Pavel M, Cwikla JB, et al. Anti-tumor effects of Lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 2016;23:191-199.
Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long- term survival. Neuroendocrinology 2017;104:26-32.
Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparision trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017;35:1695- 1703.
Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2017;28:1309-1315.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from randomized, phase III RADIANT-3 study. J Clin Oncol 2016;34:3906-3913.
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo- controlled, phase 3 study. Lancet. 2016;387:968-977.
Singh S, Carnaghi C, Buzzoni R, et al. Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology 2018;106:211-220.
Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1411-1422.
Pavel ME, Hainsworth JD, Baudin E, eta l. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;378:2005-2012.
Pavel ME, Baudin E, Oberg KE, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumors and carcinoid syndrome: final overall survival from the ramdomized, placebo-controlled, phase 3 trial RADIANT-2 study. Ann Oncol 2017;28:1569-1575.
Ema. Available at https://www.ema.europa.eu/en/documents/product-information/a finitor-epar-product-information_en.pdf. Accessed November 29, 2019.
Panzuto F, Rinzivillo M, Spada F, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas 2017;46:302-305.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 501-513.
Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017;28:339-343.
Vinik A, Bottomley A, Korytowsky B, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from international phase III trial. Target Oncol 2016;11:815-824.
Ema. Available at https://ec.europa.eu/health/documents/community- register/2016/20161109136193/anx_136193_en.pdf. Accessed November 29, 2019.
Raymond E, Kulke MH, Qin S, et al. Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours. Neuroendocrinology 2018;107:237-245.
Pellat A, Dreyer C, Couffignal C, et al. Clinical and biomarker evaluations of sunitinib in patients with Grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107:24-31.
Xu J, Shen L, Zhou Z, et al. Efficacy and safety of surufatinib in patients with well- differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the ramdomize phase III study (SANET-ep). Ann Oncol 2019; 30:v851-v934.
Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cáncer Tratar Rev. 2016;44:26-41.
Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin- fluoracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
Clewemar Antonodimitrakis P, Sundin A, Wassberg C, et al. Streptozocin and 5- fluoracil for the treatment of pancreatic neuroendocrine tumors: Efficacy, prognostic factors and toxicity. Neuroendocrinology 2016;103:345-353.
Dilz LM, Denecke T, Steffen IG, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015;51:1253-1262.
Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Cancer de Endocr Relat. 2016;23:759-767.
Kunz PL, Catalano PJ, Nimeiri HS, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumours: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol 2015; 33:TPS4145.
Walter T, van Brakel B, Vercherat C, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 2015;112:523-531.
Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014;120:2814-2023.
Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high- grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinoma. Neuroendocrinology. 2016;103:186-194.
Knigge U, Capdevila J, Bartsch DK, et al. ENETS Consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology 2017;105:310- 319.
Ema. Available in https://www.ema.europa.eu/en/documents/overvi ew/lutathera- epar-summary-public_en.pdf. Accessed November 29, 2019.
Oberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol 2020;31:202-212.
Publicado
2022-10-25
Cómo citar
Fuentes, M. B. (2022). Tratamiento oncológico de los tumores neuroendocrinos pancreáticos: Oncological treatment of pancreatic neuroendocrine tumors. Revista Profesional HígadoSano, (24), 20-31. https://doi.org/10.5281/zenodo.7516132
Sección
Artículos
